Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye
Vedran Radojcic1 and Leo Luznik2
1Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah, USA.
2Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Address correspondence to: Vedran Radojcic, University of Utah Huntsman Cancer Institute, Room 5263, 2000 Cir of Hope Drive, Salt Lake City, Utah 84105, USA. Phone: 801.213.6109; Email: vedran.radojcic@hsc.utah.edu. Or to: Leo Luznik, Johns Hopkins University, Cancer Research Building I, Room 2M88, 1650 Orleans Street, Baltimore, Maryland 21231, USA. Phone: 410.502.7732; Email: luznile@jhmi.edu.
Find articles by
Radojcic, V.
in:
JCI
|
PubMed
|
Google Scholar
|
1Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, Utah, USA.
2Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
Address correspondence to: Vedran Radojcic, University of Utah Huntsman Cancer Institute, Room 5263, 2000 Cir of Hope Drive, Salt Lake City, Utah 84105, USA. Phone: 801.213.6109; Email: vedran.radojcic@hsc.utah.edu. Or to: Leo Luznik, Johns Hopkins University, Cancer Research Building I, Room 2M88, 1650 Orleans Street, Baltimore, Maryland 21231, USA. Phone: 410.502.7732; Email: luznile@jhmi.edu.
Find articles by Luznik, L. in: JCI | PubMed | Google Scholar
First published May 6, 2019 - More info
J Clin Invest. 2019;129(6):2189–2191. https://doi.org/10.1172/JCI128710.
© 2019 American Society for Clinical Investigation
For high-risk and refractory hematological malignancies, allogeneic hematopoietic stem cell transplantation (alloHSCT) is the only available curative therapy, with benefits derived from the antigenic disparity between recipient cancer and the incoming immune system. This immunologic mismatch can also lead to lethal graft-versus-host disease (GVHD), and immunosuppression strategies, including high-dose posttransplantation cyclophosphamide (PTCy), have been developed to allow for safe alloHSCT delivery. In this issue of JCI, Wachsmuth et al. present the results of preclinical studies designed to evaluate the mechanisms that underlie efficacy of PTCy after alloHSCT. The results of this study challenge previous reports indicating that alloreactive T cell elimination and thymic clonal deletion are primary mediators of PTCy efficacy and provide strong evidence to support FoxP3+CD4+ Tregs as important effectors of PTCy benefits.
- Purchase this article
- $10
- Purchasing this article will give you full access for the calendar year.
- Purchase Site Pass
- $25
- This will give you access to every article on the site for 24 hours.
- Online subscription
- $95
- Individual online subscriptions give you full online access for the calendar year.
- Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
- Print subscription
- $830
- Individual print subscriptions give you the print journal and full online access for the year.
- JCI This Month subscription
- $125
- JCI This Month is a 16- to 20-page overview of the articles published each month
- Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
- *Price outside U.S. and Canada: $225.
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)